References
- Lowis SP, Newel DR. Etoposide for the treatment of pediatric tumors. What is the best way to give it? Eur J Cancer. 1996;32A:2291–2297.
- Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14: 399–404.
- Kushner B, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17:3221–3225.
- Ashley D, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose etoposide. J Clin Oncol. 1996;14: 1922–1927.
- Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol. 1997;29:28–32.
- Korones D, Fisher P, Cohen K, Dubowy R. No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol. 2000;35:80–82.
- Schouten Van Meeteren AYN, Moll AF, Imhof SM, Veerman AJP. Chemotherapy for retinoblastoma. An expanding area of clinical research. Med Pediatr Oncol. 2002; 38:428–438.
- Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma. A study of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1995;13: 902–909.
- Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res. 1989;9:469–474.
- Mendelsohn ME, Abramson DH, Madden T, et al. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116:1209–1212.